Abstract
Differing views were heard at the Drug Discovery Technology 2001 conference held in August in Boston, MA, USA on how to identify new drug targets through genomics (bmn.com, 16 August). Speakers from large and small pharmaceutical companies discussed the merits of parallel processing and automated high-throughput testing versus ‘one-at-a-time’ gene screening. Pfizer, inc (Groton, NJ, USA) reported some success in targeting a family of phosphodiesterase genes in search of new treatments for respiratory illness and erectile dysfunction, but experienced very high failure rates in phase 1 trials. MJD
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call